In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Labopharm To Pursue FDA Approval For Once-Daily Tramadol

This article was originally published in The Pink Sheet Daily

Executive Summary

As part of Ortho-McNeil's partnership with Biovail for extended release tramadol, Ortho is relinquishing exclusivity on the once-daily formulation - opening the way for Labopharm to pursue approval of its own product

You may also be interested in...



FDA Needs Six Months To Review Labopharm’s Once-Daily Tramadol

Cipher’s competing tramadol formulation has a user fee date more than a month ahead of the June deadline for Labopharm’s product.

FDA Needs Six Months To Review Labopharm’s Once-Daily Tramadol

Cipher’s competing tramadol formulation has a user fee date more than a month ahead of the June deadline for Labopharm’s product.

Ouch: Cipher Maintains Phase III Trial Failure Of Tramadol Will Not Impact NDA

Ontario drug maker may have to contend with two other competitors in the synthetic opioid space.

Related Content

Topics

UsernamePublicRestriction

Register

PS061343

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel